[go: up one dir, main page]

EA201790078A1 - Ингибиторы mnk и связанные с ними способы - Google Patents

Ингибиторы mnk и связанные с ними способы

Info

Publication number
EA201790078A1
EA201790078A1 EA201790078A EA201790078A EA201790078A1 EA 201790078 A1 EA201790078 A1 EA 201790078A1 EA 201790078 A EA201790078 A EA 201790078A EA 201790078 A EA201790078 A EA 201790078A EA 201790078 A1 EA201790078 A1 EA 201790078A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
formula
related methods
pharmaceutically acceptable
mnk inhibitors
Prior art date
Application number
EA201790078A
Other languages
English (en)
Other versions
EA033920B1 (ru
Inventor
Зигфрид Х. Райх
Пол А. Шпренгелер
Стефен И. Веббер
Алан Синь Сян
Джастин Томас Эрнст
Original Assignee
Эффектор Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эффектор Терапьютикс, Инк. filed Critical Эффектор Терапьютикс, Инк.
Publication of EA201790078A1 publication Critical patent/EA201790078A1/ru
Publication of EA033920B1 publication Critical patent/EA033920B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение относится к соединениям формулы (I)их или стереоизомеру, таутомеру или фармацевтически приемлемой соли, где R, R, R, R, R, R, R, R, R, W, W, Y и n такие, как определены в описании. Также описаны фармацевтически приемлемые композиции соединений формулы I, а также способы применения соединений формулы I и фармацевтически приемлемых композиций соединения формулы I в качестве ингибиторов Mnk, a также в качестве терапевтических средств для лечения заболеваний, таких как рак.
EA201790078A 2014-06-25 2015-06-24 ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ EA033920B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462017112P 2014-06-25 2014-06-25
PCT/US2015/037416 WO2015200481A1 (en) 2014-06-25 2015-06-24 Mnk inhibitors and methods related thereto

Publications (2)

Publication Number Publication Date
EA201790078A1 true EA201790078A1 (ru) 2017-05-31
EA033920B1 EA033920B1 (ru) 2019-12-10

Family

ID=53724447

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790078A EA033920B1 (ru) 2014-06-25 2015-06-24 ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ

Country Status (24)

Country Link
US (6) US9382248B2 (ru)
EP (2) EP3521289B1 (ru)
JP (2) JP6615797B2 (ru)
KR (1) KR102460389B1 (ru)
CN (2) CN106795162B (ru)
AU (1) AU2015279984B2 (ru)
BR (1) BR112016029916B1 (ru)
CA (1) CA2953365C (ru)
CL (1) CL2016003293A1 (ru)
CO (1) CO2017000399A2 (ru)
DK (2) DK3521289T3 (ru)
EA (1) EA033920B1 (ru)
ES (2) ES2728201T3 (ru)
FI (1) FI3521289T3 (ru)
IL (1) IL249557B (ru)
MX (1) MX375323B (ru)
MY (1) MY189363A (ru)
NZ (1) NZ728007A (ru)
PE (1) PE20170321A1 (ru)
PH (1) PH12016502504B1 (ru)
SG (2) SG11201610511YA (ru)
TW (1) TWI713455B (ru)
WO (1) WO2015200481A1 (ru)
ZA (1) ZA201700241B (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11952375B2 (en) 2018-10-24 2024-04-09 Effector Therapeutics Inc. Crystalline forms of Mnk inhibitors
RU2821258C2 (ru) * 2018-10-24 2024-06-19 Эффектор Терапьютикс, Инк. Способ получения кристаллической формы ингибиторов mnk

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
KR20240038145A (ko) * 2015-04-20 2024-03-22 이펙터 테라퓨틱스, 인크. 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제
AU2016343687A1 (en) 2015-10-29 2018-06-07 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
MX2018005203A (es) 2015-10-29 2018-07-06 Effector Therapeutics Inc Compuestos de pirrolo-, pirazolo-, imidazo-pirimidina y pirrolo-, pirazolo-, imidazo-piridina que inhiben cinasas 1 y 2 de interaccion con proteina cinasas activadas por mitogenos (mnk1 y mnk2).
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
WO2017117052A1 (en) * 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
ES2992063T3 (es) 2016-11-28 2024-12-09 Praxis Prec Medicines Inc Compuestos y procedimientos de uso de los mismos
TW201831479A (zh) * 2017-01-20 2018-09-01 德商拜耳製藥公司 經取代二氫咪唑并吡啶二酮
WO2018134335A1 (en) * 2017-01-20 2018-07-26 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
WO2018148745A1 (en) * 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
PE20191349A1 (es) * 2017-02-14 2019-09-30 Effector Therapeutics Inc Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018218038A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
WO2019035951A1 (en) 2017-08-15 2019-02-21 Praxis Precision Medicines, Inc. COMPOUNDS AND THEIR METHODS OF USE
CA3079607A1 (en) 2017-10-19 2019-04-25 Effector Therapeutics, Inc. Benzimidazole-indole inhibitors of mnk1 and mnk2
IL309843A (en) 2018-05-30 2024-02-01 Praxis Prec Medicines Inc ion channel modulators
WO2020108619A1 (zh) * 2018-11-30 2020-06-04 上海迪诺医药科技有限公司 Mnk抑制剂
CN111484494B (zh) 2019-01-29 2022-09-13 诺沃斯达药业(上海)有限公司 抑制mnk1和mnk2的多环化合物
US20220226321A1 (en) * 2019-05-23 2022-07-21 Board Of Regents, The University Of Texas System Inhibitor of mnk for the treatment of neuropathic pain
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
CN114269756B (zh) 2019-07-02 2024-05-14 效应疗法股份有限公司 抑制eif4e的4-氧代-3,4-二氢吡啶并[3,4-d]嘧啶化合物
JP2021008453A (ja) 2019-07-02 2021-01-28 エフェクター・セラピューティクス，インコーポレーテッド 翻訳阻害剤およびその使用
US20220251085A1 (en) * 2019-07-21 2022-08-11 University Of Virginia Patent Foundation Cysteine binding compositions and methods of use thereof
LT4063364T (lt) * 2019-11-18 2024-11-11 Jumbo Drug Bank Co., Ltd. Pirolotriazinų junginiai, veikiantys kaip mnk inhibitoriai
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
CA3183551A1 (en) * 2020-06-30 2022-01-06 Theodore J. Price Pyridine-1,5-diones exhibiting mnk inhibition and their method of use
EP4200296A1 (en) * 2020-08-20 2023-06-28 Hepagene Therapeutics (HK) Limited Mnk inhibitors
US11925642B2 (en) 2020-10-08 2024-03-12 Board Of Regents, The University Of Texas System Regulation of eIF4E activity for migraine therapy
AU2022271540B2 (en) * 2021-05-08 2025-02-27 Jumbo Drug Bank Co., Ltd. Salt form of pyrrolotriazine compound, crystal form thereof, and preparation method therefor
JP2024525480A (ja) * 2021-06-30 2024-07-12 ４イー セラピューティクス， インコーポレイテッド Ｍｎｋ阻害を示すスピロ環式ピリジン－１，５－ジオン及びその使用方法
CA3228265A1 (en) * 2021-08-05 2023-02-09 4E Therapeutics, Inc. Methods of treating migraine with mnk inhibitors
CN114853756B (zh) * 2022-03-31 2023-03-28 武汉九州钰民医药科技有限公司 化合物Tomivosertib的制备工艺
CN114671869B (zh) * 2022-03-31 2023-06-30 武汉九州钰民医药科技有限公司 化合物Tomivosertib的合成方法
CN114736205B (zh) * 2022-03-31 2023-03-03 武汉九州钰民医药科技有限公司 化合物Tomivosertib的制备方法
CN118785912A (zh) * 2022-07-19 2024-10-15 成都嘉葆药银医药科技有限公司 一种吡咯并三嗪类化合物在制备抗肿瘤药物中的应用
CN116425750A (zh) * 2023-02-10 2023-07-14 诺沃斯达药业(上海)有限公司 一种mnk抑制剂化合物的盐、晶体及其制备方法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491144A (en) 1991-05-30 1996-02-13 Ciba-Geigy Corporation Substituted diaminophthalimides and analogues
US9357797B2 (en) * 1999-11-06 2016-06-07 Janmarie Hornack Dietary supplement containing alkaline electrolyte buffers
EP1401449B1 (en) * 2001-06-05 2007-04-25 Lilly Icos LLC Tetracyclic compounds as pde5-inhibitors
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
EP1912939A1 (en) 2005-08-12 2008-04-23 AstraZeneca AB Metabotropic glutamate-receptor-potentiating isoindolones
DE602007004618D1 (de) * 2006-06-22 2010-03-18 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
PL2134689T3 (pl) 2007-03-16 2014-10-31 Scripps Research Inst Inhibitory kinazy ognisk adhezyjnych
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
JP2009173629A (ja) 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
BRPI0918971A2 (pt) * 2008-08-26 2015-12-01 Boehringer Ingelheim Int tienopirimidinas para composições farmacêuticas
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8609676B2 (en) 2009-08-04 2013-12-17 Merck Sharp & Dohme, Corp. 4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
MX2013003695A (es) 2010-10-01 2013-05-20 Bayer Ip Gmbh Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida.
EP3042910B1 (en) 2010-11-30 2019-01-09 Gilead Pharmasset LLC 2'-spiro-nucleosides for use in the therapy of hepatitis c
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US9447087B2 (en) 2011-09-23 2016-09-20 University Of Utah Research Foundation Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders
RU2625799C2 (ru) 2011-12-30 2017-07-19 Ханми Фарм. Ко., Лтд. ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ
EP2831080B1 (en) 2012-03-29 2017-03-15 Francis Xavier Tavares Lactam kinase inhibitors
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
EP2852593A1 (en) * 2012-05-21 2015-04-01 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidines
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014072244A1 (en) * 2012-11-09 2014-05-15 Boehringer Ingelheim International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
GB2508652A (en) 2012-12-07 2014-06-11 Agency Science Tech & Res Heterocyclic piperazine derivatives
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
CA2901527A1 (en) 2013-02-20 2014-08-28 Bayer Pharma Aktiengesellschaft Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors
TW201605867A (zh) 2013-11-20 2016-02-16 拜耳製藥公司 噻吩并嘧啶
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
JP2018501250A (ja) * 2014-12-19 2018-01-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ｍｋｎｋ１およびｍｋｎｋ２阻害剤としてのピラゾロピリジンアミン
MX2018005203A (es) 2015-10-29 2018-07-06 Effector Therapeutics Inc Compuestos de pirrolo-, pirazolo-, imidazo-pirimidina y pirrolo-, pirazolo-, imidazo-piridina que inhiben cinasas 1 y 2 de interaccion con proteina cinasas activadas por mitogenos (mnk1 y mnk2).
AU2016343687A1 (en) 2015-10-29 2018-06-07 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
GB201520500D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
GB201520499D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11952375B2 (en) 2018-10-24 2024-04-09 Effector Therapeutics Inc. Crystalline forms of Mnk inhibitors
RU2821258C2 (ru) * 2018-10-24 2024-06-19 Эффектор Терапьютикс, Инк. Способ получения кристаллической формы ингибиторов mnk

Also Published As

Publication number Publication date
TWI713455B (zh) 2020-12-21
US20150376181A1 (en) 2015-12-31
EA033920B1 (ru) 2019-12-10
US20190209560A1 (en) 2019-07-11
PH12016502504B1 (en) 2022-07-13
MY189363A (en) 2022-02-07
NZ728007A (en) 2023-03-31
CL2016003293A1 (es) 2017-09-08
JP2020063251A (ja) 2020-04-23
ZA201700241B (en) 2022-05-25
MX375323B (es) 2025-03-06
US9814718B2 (en) 2017-11-14
EP3160966B1 (en) 2019-02-27
WO2015200481A1 (en) 2015-12-30
FI3521289T3 (fi) 2024-01-09
WO2015200481A8 (en) 2016-06-30
CO2017000399A2 (es) 2017-04-28
US20160317536A1 (en) 2016-11-03
US20210338673A1 (en) 2021-11-04
KR102460389B1 (ko) 2022-10-27
EP3521289A1 (en) 2019-08-07
TW201613918A (en) 2016-04-16
PH12016502504A1 (en) 2017-04-10
CN110183449A (zh) 2019-08-30
BR112016029916A2 (pt) 2017-08-22
US20180085368A1 (en) 2018-03-29
MX2016017030A (es) 2017-09-11
EP3160966A1 (en) 2017-05-03
CN106795162A (zh) 2017-05-31
CN106795162B (zh) 2019-07-16
CA2953365A1 (en) 2015-12-30
US20170266185A1 (en) 2017-09-21
IL249557A0 (en) 2017-02-28
SG11201610511YA (en) 2017-01-27
DK3160966T3 (da) 2019-05-27
CA2953365C (en) 2023-08-08
JP6979439B2 (ja) 2021-12-15
AU2015279984A1 (en) 2017-01-19
KR20170023145A (ko) 2017-03-02
US9669031B2 (en) 2017-06-06
PE20170321A1 (es) 2017-04-05
ES2728201T3 (es) 2019-10-22
JP2017519782A (ja) 2017-07-20
US9382248B2 (en) 2016-07-05
BR112016029916B1 (pt) 2023-12-12
EP3521289B1 (en) 2023-10-25
CN110183449B (zh) 2022-08-19
AU2015279984B2 (en) 2019-12-05
ES2967536T3 (es) 2024-04-30
DK3521289T3 (da) 2024-01-15
SG10201811384TA (en) 2019-01-30
IL249557B (en) 2021-10-31
JP6615797B2 (ja) 2019-12-04

Similar Documents

Publication Publication Date Title
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA201790085A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201692513A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201692267A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
EA201692470A1 (ru) Фармацевтические комбинации
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM